1201 related articles for article (PubMed ID: 9417395)
1. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
3. [alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo].
Hantouche EG; Guelfi JD; Comet D
Encephale; 1998; 24(5):469-79. PubMed ID: 9850822
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
Small GW; Bystritsky A
J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
[TBL] [Abstract][Full Text] [Related]
5. [Modification of cognitive functions by 2 anxiolytic treatments in patients suffering from generalized anxiety].
Samuelian JC; Billardon M; Guillou N
Encephale; 1995; 21(2):147-53. PubMed ID: 7781586
[TBL] [Abstract][Full Text] [Related]
6. [Value of hydroxyzine in generalized anxiety disorder: controlled double-blind study versus placebo].
Ferreri M; Hantouche EG; Billardon M
Encephale; 1994; 20(6):785-91. PubMed ID: 7875114
[TBL] [Abstract][Full Text] [Related]
7. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
8. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
[TBL] [Abstract][Full Text] [Related]
9. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety].
Lôo H; Malka R; Hantouche E; Lancrenon S; Guelfi JD
Encephale; 1991; 17(4):295-300. PubMed ID: 1959498
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of generalized anxiety: new pharmacologic approaches].
Boulenger JP
Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
[TBL] [Abstract][Full Text] [Related]
11. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
Lemoine P; Rouillon F; Pouget D
Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
[TBL] [Abstract][Full Text] [Related]
13. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
Lydiard RB; Ballenger JC; Rickels K
J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
Nguyen N; Fakra E; Pradel V; Jouve E; Alquier C; Le Guern ME; Micallef J; Blin O
Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the effects of the combination drug lorazepam plus diphenhydramine (Somnium) versus lorazepam on the noopsyche, thymopsyche and psychophysiology in nonorganic insomnia related to generalized anxiety disorder.
Grünberger J; Saletu B; Linzmayer L; Böck G; Weissgram S; Brandstaätter N; Frey R; Saletu-Zyhlarz G
Methods Find Exp Clin Pharmacol; 1997 Nov; 19(9):645-54. PubMed ID: 9500129
[TBL] [Abstract][Full Text] [Related]
17. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study.
Gerra G; Zaimovic A; Giusti F; Moi G; Brewer C
Addict Biol; 2002 Oct; 7(4):385-95. PubMed ID: 14578014
[TBL] [Abstract][Full Text] [Related]
18. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
[TBL] [Abstract][Full Text] [Related]
19. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
Mercier-Guyon C; Chabannes JP; Saviuc P
Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
[TBL] [Abstract][Full Text] [Related]
20. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
Cohn JB; Wilcox CS
J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
